Erlotinib Promising for Cancer Prevention in FAP

Findings from this phase 2 trial support further study of erlotinib as "an effective, acceptable cancer preventive agent for FAP-associated gastrointestinal polyposis," the study team says.
Medscape Medical News

source https://www.medscape.com/viewarticle/979611?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?